Skip to main content

Advertisement

SpringerLink
Log in

Neuronal Life Span Versus Health Span: Principles of Natural Selection at Work in the Degenerating Brain

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Impaired nutrient delivery to the brain due to decreased blood flow contributes to cognitive decline and dementia in Alzheimer’s disease (AD). Considering this, many studies have suggested that neuroprotective agents like those used in stroke could prevent AD onset or progression by promoting cell survival. However, research in the past decade suggests that the culprit behind the cognitive loss in AD models is actually the soluble tau accumulating inside of surviving neurons. In fact, tau reductions improve cognition in mouse models of AD, even those that only deposit amyloid plaques. There is emerging evidence that neuroprotection alone in these AD models may be insufficient to restore neuron function and cognition. Only when soluble tau is reduced on a neuroprotective background could memory be rescued. Thus, once a neuron begins to accumulate tau, it may survive in a malfunctioning capacity, leading to impaired electrical signaling and memory formation in the brain. These data imply that multiple drugs may be necessary to ameliorate the different disease components. In fact, strategies to preserve neurons without affecting the soluble protein burden within neurons may accelerate the disease course.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Abisambra JF, Blair LJ, Hill SE et al (2010) Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice. J Neurosci 30:15374–15382

    Article  PubMed  CAS  Google Scholar 

  • Albani D, Polito L, Signorini A, Forloni G (2010) Neuroprotective properties of resveratrol in different neurodegenerative disorders. Biofactors 36:370–376

    Article  PubMed  CAS  Google Scholar 

  • Andorfer C, Kress Y, Espinoza M et al (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86:582–590

    Article  PubMed  CAS  Google Scholar 

  • Bell RD, Deane R, Chow N et al (2009) SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 11:143–153

    Article  PubMed  CAS  Google Scholar 

  • Brewer GJ (2010) Why vitamin E therapy fails for treatment of Alzheimer’s disease. J Alzheimers Dis 19:27–30

    PubMed  Google Scholar 

  • Chow N, Bell RD, Deane R et al (2007) Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer’s phenotype. Proc Natl Acad Sci USA 104:823–828

    Article  PubMed  CAS  Google Scholar 

  • Dayanandan R, Van Slegtenhorst M, Mack TG et al (1999) Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett 446:228–232

    Article  PubMed  CAS  Google Scholar 

  • de Calignon A, Fox LM, Pitstick R et al (2010) Caspase activation precedes and leads to tangles. Nature 26:787–789

    Google Scholar 

  • Ghiso J, Matsubara E, Koudinov A et al (1993) The cerebrospinal-fluid soluble form of Alzheimer’s amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane–attack complex. Biochem J 293(Pt 1):27–30

    PubMed  CAS  Google Scholar 

  • Grundman M (2000) Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 71:630S–636S

    PubMed  CAS  Google Scholar 

  • Harada A, Oguchi K, Okabe S et al (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369:488–491

    Article  PubMed  CAS  Google Scholar 

  • Hwang IK, Yoo KY, Li H et al (2009) Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus. J Neurosci Res 87:2126–2137

    Article  PubMed  CAS  Google Scholar 

  • Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci 5:347–360

    Article  PubMed  CAS  Google Scholar 

  • Ittner LM, Ke YD, Delerue F et al (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142:387–397

    Article  PubMed  CAS  Google Scholar 

  • Jinwal UK, Miyata Y, Koren J 3rd et al (2009) Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci 29:12079–12088

    Article  PubMed  CAS  Google Scholar 

  • Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int 54:111–118

    Article  PubMed  CAS  Google Scholar 

  • Kim D, Nguyen MD, Dobbin MM et al (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J 26:3169–3179

    Article  PubMed  CAS  Google Scholar 

  • Kimura T, Fukuda T, Sahara N et al (2010) Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J Biol Chem 285:38692–38699

    Article  PubMed  CAS  Google Scholar 

  • King ME, Kan HM, Baas PW, Erisir A, Glabe CG, Bloom GS (2006) Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 175:541–546

    Article  PubMed  CAS  Google Scholar 

  • Matsubara E, Ghiso J, Frangione B et al (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer’s disease and Down’s syndrome. Ann Neurol 45:537–541

    Article  PubMed  CAS  Google Scholar 

  • Medina DX, Caccamo A, Oddo S (2011) Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 21(2):140–149

    Article  PubMed  CAS  Google Scholar 

  • Morshedi D, Rezaei-Ghaleh N, Ebrahim-Habibi A, Ahmadian S, Nemat-Gorgani M (2007) Inhibition of amyloid fibrillation of lysozyme by indole derivatives—possible mechanism of action. FEBS J 274:6415–6425

    PubMed  CAS  Google Scholar 

  • Niwa K, Younkin L, Ebeling C et al (2000) Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci USA 97:9735–9740

    Article  PubMed  CAS  Google Scholar 

  • Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C (2001) A beta-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 281:H2417–H2424

    PubMed  CAS  Google Scholar 

  • O’Connor T, Sadleir KR, Maus E et al (2008) Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60:988–1009

    Article  PubMed  Google Scholar 

  • O’Leary JC 3rd, Li Q, Marinec P et al (2010) Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 5:45

    Article  PubMed  Google Scholar 

  • Paris D, Townsend KP, Humphrey J, Obregon DF, Yokota K, Mullan M (2002) Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis 161:293–299

    Article  PubMed  CAS  Google Scholar 

  • Petersen RC, Thomas RG, Grundman M et al (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352:2379–2388

    Article  PubMed  CAS  Google Scholar 

  • Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 99:6364–6369

    Article  PubMed  CAS  Google Scholar 

  • Redwine JM, Kosofsky B, Jacobs RE et al (2003) Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci USA 100:1381–1386

    Article  PubMed  CAS  Google Scholar 

  • Roberson ED, Scearce-Levie K, Palop JJ et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316:750–754

    Article  PubMed  CAS  Google Scholar 

  • Santacruz K, Lewis J, Spires T et al (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476–481

    Article  PubMed  CAS  Google Scholar 

  • Schwarzman AL, Gregori L, Vitek MP et al (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 91:8368–8372

    Article  PubMed  CAS  Google Scholar 

  • Shibata M, Yamada S, Kumar SR et al (2000) Clearance of Alzheimer’s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J Clin Invest 106:1489–1499

    Article  PubMed  CAS  Google Scholar 

  • Simon-Sanchez J, Schulte C, Bras JM et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41:1308–1312

    Article  PubMed  CAS  Google Scholar 

  • Tucker KL, Meyer M, Barde YA (2001) Neurotrophins are required for nerve growth during development. Nat Neurosci 4:29–37

    Article  PubMed  CAS  Google Scholar 

  • Urmoneit B, Prikulis I, Wihl G et al (1997) Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab Invest 77:157–166

    PubMed  CAS  Google Scholar 

  • Wagner U, Utton M, Gallo JM, Miller CC (1996) Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 109(Pt 6):1537–1543

    PubMed  CAS  Google Scholar 

  • Wang J, Ho L, Zhao Z et al (2006) Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer’s disease. FASEB J 20:2313–2320

    Article  PubMed  CAS  Google Scholar 

  • Wischik C, Staff R (2009) Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging 13:367–369

    Article  PubMed  CAS  Google Scholar 

  • Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 93:11213–11218

    Article  PubMed  CAS  Google Scholar 

  • Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN (1997) Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem 68:721–725

    Article  PubMed  CAS  Google Scholar 

  • Yuan A, Kumar A, Peterhoff C, Duff K, Nixon RA (2008) Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci 28:1682–1687

    Article  PubMed  CAS  Google Scholar 

  • Zlokovic BV (2008) The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. USF Health Byrd Alzheimer’s Institute, Tampa, FL, 33613, USA

    John C. O’Leary III, John Koren III & Chad A. Dickey

  2. Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida, 4001 E. Fletcher Ave. MDC 7, Tampa, FL, 33613, USA

    Chad A. Dickey

Authors
  1. John C. O’Leary III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Koren III
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chad A. Dickey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chad A. Dickey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Leary, J.C., Koren, J. & Dickey, C.A. Neuronal Life Span Versus Health Span: Principles of Natural Selection at Work in the Degenerating Brain. J Mol Neurosci 45, 467–472 (2011). https://doi.org/10.1007/s12031-011-9540-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-011-9540-4

Keywords

Search

Navigation